Skip to content
Guardian Bio logo

Guardian Bio

Guardian Bio is a YC Summer 2022 (S22) company. Based in Boston, MA, USA. Team of 2.

  • Biotech
  • Healthcare
  • Therapeutics
  • Oncology

About Guardian Bio

GPAgent's own fund-neutral profile, written from public information. Updated Oct 5, 2026.

Summary

Guardian Bio develops a personalized dendritic cell therapy for late-stage solid tumor patients. The process takes a patient's own stem cells, converts them into therapeutic dendritic cells trained against that patient's specific tumor targets, and reintroduces them to reactivate the immune system's cancer-killing response. This replaces the broadly dysfunctional dendritic cell activity that undermines both native immunity and existing cancer treatments.

From the Y Combinator listing

How Guardian Bio describes itself in Y Combinator's public directory. Original listing (opens in a new tab)

Dendritic cell-based platform for cancer therapy

Your immune system is your body’s best weapon and defense against cancer. It is only when it is overcome that cancer develops into full blown disease. Dendritic cells sit at the helm of the immune system, directing and dictating immune responses. Data has shown dendritic cells are often dysfunctional in cancer patients, and that this dysfunction is a bottleneck for other therapies. Guardian Bio’s approach is focused on creating a dendritic cell-based product which drives anti-tumor activity through activating the killers of the immune system AND training them against multiple cancer targets. We take stem cells from cancer patients, turn them into specific therapeutic dendritic cells specially trained against that patient’s tumor, and re-introduce them back into the body. Our therapeutic dendritic cells revitalize the killers of the immune system and give them the kickstart they need to fight - and win - against cancer.

Facts

Industry
Healthcare / Healthcare -> Therapeutics
Location
Boston, MA, USA
Team size
2
Status
Active
Stage
Early

Founders (2)

Score every batch against your own thesis

GPAgent's sourcing agent reads every company in a batch, scores each one against your fund's thesis in a private workspace, and lines up the founders worth meeting before Demo Day. You decide who to contact. Your scores, notes, and pipeline never appear on these pages.

How Accelerator intelligence works